---
title: "Nurtec ODT (rimegepant), all indications: Specific populations questions"
description: "Specific populations questions on Nurtec ODT (rimegepant) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Nurtec ODT be used during pregnancy? Can Nurtec ODT be used while breastfeeding? Is Nurtec ODT approved for children? Has Nurtec ODT been studied in adults 65 and older? 3 further questions follow. 7 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/nurtec-odt/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nurtec ODT (rimegepant), all indications: Specific populations questions

Manufacturer: Pfizer Inc  
Prescribing information: [Nurtec ODT](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036)  
Indication pages: [Acute treatment of migraine](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine)

## Pregnancy and breastfeeding

<a id="nurtec-pregnancy"></a>

### Can Nurtec ODT be used during pregnancy?

> “There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to NURTEC ODT during pregnancy. For more information, healthcare providers or patients are encouraged to contact: 1-877-366-0324, email crgnurtecpregnancyregistry@thermofisher.com, or visit nurtecpregnancyregistry.com.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=There%20is%20a%20pregnancy%20exposure,email%20crgnurtecpregnancyregistry%40thermofisher.com%2C%20or%20visit%20nurtecpregnancyregistry.com.)

> “There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women. In animal studies, oral administration of rimegepant during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of skeletal variations) at exposures greater than those used clinically and which were associated with maternal toxicity (see Data).”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=There%20are%20no%20adequate%20data,with%20maternal%20toxicity%20%28see%20Data%29.)

> “Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Published%20data%20have%20suggested%20that,and%20gestational%20hypertension%20during%20pregnancy.)

<a id="nurtec-breastfeeding"></a>

### Can Nurtec ODT be used while breastfeeding?

> “A lactation study was conducted, and the results have established a relative infant dose of less than 1% of the maternal weight-adjusted dose and the milk-to-plasma ratio of 0.20 (see Data). These data support that transfer of rimegepant into breastmilk is low. There are no data on the effects of rimegepant on a breastfed infant or on milk production.
>
> The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NURTEC ODT and any potential adverse effects on the breastfed infant from NURTEC ODT or from the underlying maternal condition.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=A%20lactation%20study%20was%20conducted%2C,from%20the%20underlying%20maternal%20condition.)

> “A study was conducted in twelve healthy adult lactating women who were between 2 weeks and 6 months postpartum and were administered a single oral dose of rimegepant 75 mg. The relative infant dose was <1%. The average milk to plasma ratio was 0.20.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=A%20study%20was%20conducted%20in,to%20plasma%20ratio%20was%200.20.)

## Specific populations

<a id="nurtec-children"></a>

### Is Nurtec ODT approved for children?

> “Safety and effectiveness in pediatric patients have not been established.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Safety%20and%20effectiveness%20in%20pediatric%20patients%20have%20not%20been%20established.)

<a id="nurtec-older-adults"></a>

### Has Nurtec ODT been studied in adults 65 and older?

> “In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. Clinical studies of NURTEC ODT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=In%20pharmacokinetic%20studies%2C%20no%20clinically,respond%20differently%20from%20younger%20patients.)

<a id="nurtec-liver"></a>

### Does Nurtec ODT need a dose adjustment for liver problems?

> “No dosage adjustment of NURTEC ODT is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Plasma concentrations of rimegepant were significantly higher in subjects with severe (Child-Pugh C) hepatic impairment. Avoid use of NURTEC ODT in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=No%20dosage%20adjustment%20of%20NURTEC,impairment%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “In a dedicated clinical study comparing the pharmacokinetics of rimegepant in subjects with mild, moderate, and severe hepatic impairment to that with normal subjects (healthy matched control), the exposure of rimegepant (Cmax and AUC) following single 75 mg dose was approximately 2-fold higher in subjects with severe impairment (Child-Pugh class C). There were no clinically meaningful differences in the exposure of rimegepant in subjects with mild (Child-Pugh class A) and moderate hepatic impairment (Child-Pugh class B) compared to subjects with normal hepatic function [see Use in Specific Populations (8.6)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Hepatic%20Impairment-,In%20a%20dedicated%20clinical%20study%20comparing%20the%20pharmacokinetics%20of%20rimegepant,Use%20in%20Specific%20Populations%20%288.6%29%5D.)

<a id="nurtec-kidney"></a>

### Does Nurtec ODT need a dose adjustment for kidney problems?

> “No dosage adjustment of NURTEC ODT is required in patients with mild, moderate, or severe renal impairment. NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. Avoid use of NURTEC ODT in patients with end-stage renal disease (CLcr <15 mL/min) [see Clinical Pharmacology (12.3)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=8.7%20Renal%20Impairment-,No%20dosage%20adjustment%20of%20NURTEC%20ODT%20is%20required%20in%20patients,mL%2Fmin%29%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

<a id="nurtec-overdose"></a>

### What should be done after a Nurtec ODT overdose?

> “There is limited clinical experience with NURTEC ODT overdosage. Treatment of an overdose of NURTEC ODT should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. No specific antidote for the treatment of rimegepant overdose is available. Rimegepant is unlikely to be significantly removed by dialysis because of high serum protein binding [see Clinical Pharmacology (12.3)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=There%20is%20limited%20clinical%20experience,binding%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

## Related pages
- [Medical information: Nurtec ODT (rimegepant): All indications](https://www.evicenter.com/medical-information/nurtec-odt)
- [Indication](https://www.evicenter.com/medical-information/nurtec-odt/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nurtec-odt/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/nurtec-odt/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/nurtec-odt/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/nurtec-odt/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/nurtec-odt/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/nurtec-odt/access-and-coverage)
